EP
JAZZ icon

Essential Partners’s Jazz Pharmaceuticals JAZZ Stock Holding History

Essential Partners’s Portfolio JAZZ Stock Details JAZZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$67.4K Sell
291
-37
-11% -$9.14K 0.03% 536
2026
Q2 		$79K Buy
328
+230
+235% +$50.4K 0.04% 483
2026
Q1 		$18.5K Buy
98
+21
+27% +$3.67K 0.01% 958
2025
Q4 		$13.1K Buy
77
+1
+1% +$153 ﹤0.01% 1063
2025
Q3 		$10K Buy
76
+8
+12% +$960 ﹤0.01% 1155
2025
Q2 		$7.22K Buy
+68
New +$7.39K ﹤0.01% 944

Other funds holding JAZZ

ACM
Argent Capital Management St Louis, Missouri $3.14B AUM 31.36% 1-Year Est. Return
Wedge Capital Management
Wedge Capital Management Charlotte, North Carolina $5.72B AUM 38.26% 1-Year Est. Return
Perpetual Ltd
Perpetual Ltd Sydney, New South Wales, Australia $6.57B AUM 14.15% 1-Year Est. Return
HWAM
Hennion & Walsh Asset Management Parsippany, New Jersey $3.42B AUM 25.82% 1-Year Est. Return
State of Alaska Department of Revenue
State of Alaska Department of Revenue Juneau, Alaska $9.6B AUM 34.67% 1-Year Est. Return
IFP Advisors
IFP Advisors Tampa, Florida $5.86B AUM 20.09% 1-Year Est. Return
Burney Company
Burney Company Reston, Virginia $3.66B AUM 27.59% 1-Year Est. Return
Wealth Enhancement Advisory Services
Wealth Enhancement Advisory Services Plymouth, Minnesota $67.3B AUM 21.9% 1-Year Est. Return
OLA
Oliver Luxxe Assets Gladstone, New Jersey $638M AUM 30.27% 1-Year Est. Return
CX Institutional
CX Institutional Auburn, Indiana $3.69B AUM 15.82% 1-Year Est. Return

Essential Partners's JAZZ Position: Q3 2026 in Review

Essential Partners reduced its Jazz Pharmaceuticals (JAZZ) stake by 11% in Q3 2026, selling an estimated $9.14K and leaving 291 shares worth $67.4K. The position accounts for 0.03% of the portfolio, ranked #536.

Essential Partners first reported a position in JAZZ in Q2 2025 and has held it in 6 quarters since. The position peaked at $79K in Q2 2026. 66 funds tracked by Wall St. Rank hold JAZZ as of Q3 2026.

  • Essential Partners held 291 shares of Jazz Pharmaceuticals worth $67.4K as of Q3 2026.
  • Essential Partners sold 37 Jazz Pharmaceuticals shares in Q3 2026, an estimated $9.14K.
  • Jazz Pharmaceuticals made up 0.03% of Essential Partners's portfolio in Q3 2026, its #536 holding.
  • Essential Partners first reported a position in Jazz Pharmaceuticals in Q2 2025 and has held it in 6 quarters since.
  • Essential Partners's Jazz Pharmaceuticals position peaked at $79K in Q2 2026.
  • 66 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q3 2026.

Based on Essential Partners's 13F filing for Q3 2026, filed 14 Oct 2026.